Evidence map›Paper›PMID 34366323›Full record

ArticleCancer biomarkers : section A of Disease markers2022

A systematic approach introduced novel targets in rectal cancer by considering miRNA/mRNA interactions in response to radiotherapy.

Solmaz Khalighfard, Mohammad Reza Kalhori, Taghi Amiriani, Amirhoushang Poorkhani, Vahid Khori, Ebrahim Esmati, Marzieh Lashkari, Ali Najafi, Ali Mohammad Alizadeh

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Solmaz KhalighfardRadiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Reza KalhoriRegenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Taghi AmirianiIschemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Amirhoushang PoorkhaniIschemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Vahid KhoriIschemic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Ebrahim EsmatiRadiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Marzieh LashkariRadiation Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Ali NajafiMolecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Ali Mohammad AlizadehBreast Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRGolestan University of Medical Sciences · IRBaqiyatallah University of Medical Sciences · IRKermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe discovery of miRNA/mRNA interactions in several biological samples prompted the researchers to explore new biomarkers in tumors.

objectiveWe aimed to investigate the interactions of miRNA/mRNA in response to radiotherapy in the plasma samples of rectal cancer patients.

methodsFive microarray datasets related to cancerous and non-cancerous individuals were first used to construct networks. The databases of Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to analyze pathway enrichment. The plasma samples were then collected from 55 patients with recently diagnosed rectal cancer and 10 healthy subjects. For radiotherapy courses, the patients have consecutively received 30 sessions of local radiation for six weeks. At last, the expression of selected genes and miRNAs was experimentally measured before and after radiotherapy by qPCR, and the protein levels of the target genes were measured by ELISA assay. We evaluated the therapeutic responses based on the tumor regression grade of the Dworak classification.

resultsWe identified 5 up-regulated and 5 down-regulated miRNAs and 8 up-regulated and 3 down-regulated genes of the databases. There was a significant increase in tumor suppressor miRNAs, including miR-101-3p, miR-145-5p, miR-26a-5p, miR-34a-5p, and a significant decrease in oncomiRs, including miR-221-3p and miR-17-5p, after radiotherapy compared to the pre-treatment. Moreover, the up-regulated miR-17-5p and miR-221-5p and the down-regulated miR-101-3p and miR-145-5p were directly related to rectal cancer through the interaction with the Wnt, RAS, PI3K, and TGF-β signaling pathways. An analysis of receiver operating characteristics showed that miRNAs 221, 17, and 23 were response-related in locally advanced rectal cancer patients.

conclusionsIt seems that monitoring the miRNA/mRNA interactions during radiotherapy can be an appropriate diagnostic tool to track the recovery process and respond to standard therapies.

Indexed as

MicroRNAsRectal NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyHumansReal-Time Polymerase Chain ReactionRNA, MessengerMicroRNAsMIRN145 microRNA, humanRNA, MessengergenemicroarraymicroRNAproteinRadiotherapyrectal cancer

Identifiers

PMID34366323
PMCPMC12364130
OpenAlexW3192739721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.